Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2007
10/18/2007US20070244115 Amino-Halogen-Imidazopyridines as Proton Pump Inhibitors
10/18/2007US20070244114 Compounds and therapeutical use thereof
10/18/2007US20070244113 Compounds and therapeutical use thereof
10/18/2007US20070244112 Novel tetrahydropyridothiophenes
10/18/2007US20070244110 Treatment of prostate cancer, melanoma or hepatic cancer
10/18/2007US20070244109 1-{3-[(6-amino-5-nitropyridin-2-yl)amino]propyl}-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide; Antidiabetic, hypotensive, antiischemic, anticarcinogenic agents; Alzheimer*s disease, obesity, polycystic ovary syndrome; brain, neurodegenerative and autoimmune diseases
10/18/2007US20070244108 Phenylsulfonamide Derivatives for Use as 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors
10/18/2007US20070244107 Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
10/18/2007US20070244106 Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
10/18/2007US20070244105 e.g. N,N-dimethyl-1-[6-(1-naphthylsulfonyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indazol-2-yl]-methanamine; serotonin receptor antagonist; antidepressant, epilepsy, schizophrenia, hyperactivity
10/18/2007US20070244104 N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases
10/18/2007US20070244103 Novel Compounds Having an Anti-Bacterial Activity
10/18/2007US20070244102 Combination of Dermaciclane and Opoids as Analgesics
10/18/2007US20070244101 Novel compositions and methods of treatment of type ii diabetes and hypertension
10/18/2007US20070244100 Derivatives of [2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic Acid and Methods of Making Them
10/18/2007US20070244099 Such as 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(3,4-diethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl}-amide; calcitonin gene related peptide (CGRP); for treatment of migraines; radioimmunoassay
10/18/2007US20070244098 Dual Small Molecule Inhibitors of Cancer and Angiogenesis
10/18/2007US20070244097 Nicotinic AcetylcholineReceptor Ligands
10/18/2007US20070244096 Fused Bicyclic Nitrogen-Containing Heterocycles
10/18/2007US20070244095 Compounds and Method for Treating Dyslipidemia
10/18/2007US20070244094 Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol
10/18/2007US20070244093 Quetiapine formulations
10/18/2007US20070244092 Therapeutic Compounds
10/18/2007US20070244091 treating bacterial infections; 6-({[(1-{2-[3-Fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-azetidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin or oxazin-3(4H)-one; antibiotics; grampositive Staphylococcus, gramnegative Haemophilus, Moraxella, Escherichia
10/18/2007US20070244090 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
10/18/2007US20070244089 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof
10/18/2007US20070244088 New Pyridine Analogues II
10/18/2007US20070244087 Anticancer agents; colon cancer or hepatocellular carcinoma; analogs of bengamide where the caprolactam ring is changed and/or substituted e.g. N-(2-Methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide
10/18/2007US20070244086 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
10/18/2007US20070244085 such as drinabant (N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide) with an excipient selected from Polysorbate 80 or PEG hydroxystearate; improved solubility makes possible oral administration
10/18/2007US20070244084 Method and intermediates for the preparation of derivatives of n (1-benzhydrylazetidin-3-yl)-n-phenylmethylsulfonamide
10/18/2007US20070244083 Using fluorouracil and/or oxaliplatin as diagnostic tools in detection of SCN1A-T1067A-SNP genetic polymorphism in the preferential and diagnosis of colorectal cancer
10/18/2007US20070244082 Anticancer Agent
10/18/2007US20070244081 Triterpene quaternary salts as biologically active surfactants
10/18/2007US20070244080 Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
10/18/2007US20070244079 Preventive/remedy for allergic diseases
10/18/2007US20070244078 Methods for Treatment, Modification and Management of Pain Using 1-Oxo-2-(2,6-Dioxopiperidin-3-yl)-4-Methylisoindoline
10/18/2007US20070244077 Composition and method of treating peripheral neuropathy
10/18/2007US20070244076 Site and Rate Selective Prodrug Formulations of D609 with Antioxidant and Anticancer Activity
10/18/2007US20070244075 Isoflavonoid Prodrugs, Compositons Thereof and Therapeutic Methods Involving Same
10/18/2007US20070244074 Stable parenteral formulation of fosphenytoin sodium
10/18/2007US20070244072 1a-Hydroxy-2-(3'-Hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof
10/18/2007US20070244071 Treatment of proliferative diseases
10/18/2007US20070244070 Use of Organic Glucosamine Salts
10/18/2007US20070244069 Method of palliating lower urinary tract infections by treatment with mannan oligosaccharides
10/18/2007US20070244068 2',3'-O-methylenestyryl-5'-alpha-(carboxymethylenephosphono)-N6-ethylaminocarbonyl-adenosine phosphate; modified mononucleoside phosphate by attaching degradation-resistant substituent on terminal phosphate; increase rate & total amount of mucin secretion; epithelial tissue, platelet aggregation diseases
10/18/2007US20070244065 Composition Comprising a Survivin Oligonucleotide and Gemcitabine for The Treatment of Cancer
10/18/2007US20070244064 Methods and compositions to induce antitumor response
10/18/2007US20070244063 Inducing angiogenesis comprising contacting endothelial cells expressing Bv8 receptor with a polypeptide comprising the amino acid sequence of SEQ ID NO:2; using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival; screening for Bv8 modulators
10/18/2007US20070244062 Antisense Compounds Targeted to Connexins and Methods of Use Thereof
10/18/2007US20070244061 Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
10/18/2007US20070244060 Therapeutic Agent for Autoimmune Disease
10/18/2007US20070244059 Method For Attentuating Virulence Of Microbial Pathogens And For Inhibiting Microbial Biofilm Formation
10/18/2007US20070244058 Galactose Derivative, Drug Carrier and Medicinal Composition
10/18/2007US20070244053 Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection
10/18/2007US20070244051 Side effect reduction; latanoprost; it is believed that TFF-peptides may be present during healing and other related processes in the eye
10/18/2007US20070244049 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
10/18/2007US20070244046 Identification and characterization of cancer stem cells and methods of use
10/18/2007US20070244040 polypeptides and carriers, used for inducing and/or enhancing apoptosis, as well as for the treatment of cancer
10/18/2007US20070244038 Methods for treating lymphocyte-associated disorders by modulation of siglec activity
10/18/2007US20070244035 Novel co-modulators of nuclear receptors and methods of detecting and treating steroid hormone-dependent diseases using same
10/18/2007US20070244031 Methods and Compositions for Homozygous Gene Inactivation Using Collections of Pre-Defined Nucleotide Sequences Complementary Chromosomal Transcripts
10/18/2007US20070244030 Method for Assessing Cancerous State
10/18/2007US20070243632 Methods for measuring platelet reactivity of patients that have received drug eluting stents
10/18/2007US20070243629 High Affinity Ligands for Influenza Virus and Methods for Their Production
10/18/2007US20070243612 Novel Compounds for Modulating Cell Proliferation
10/18/2007US20070243547 Use of tumor susceptibilty gene 101 (TSG 101) as a prognostic and diagnostic marker
10/18/2007US20070243311 Weight management system for obese animals
10/18/2007US20070243304 Omega-3 Fatty Acid Compositions With Honey
10/18/2007US20070243275 Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
10/18/2007US20070243273 Reduction of the Deleterious Effects of Tobacco Smoking
10/18/2007US20070243270 prevent skin damage caused by ultraviolet radiation by administering a oral dosage of alpha-lipoic acid, n-acetyl cysteine, green tea extract, turmeric extract, and quercetin, and applying s topical dosage form comprising plant extracts of berry, bitter orange peel, lemon, cucumber and herbs
10/18/2007US20070243269 Saponin and preservative compositions and methods
10/18/2007US20070243268 Compositions for regulating intestinal disorders and methods of use thereof
10/18/2007US20070243266 N-[1(R)-(3H-imidazo[4,5-b]pyridin-2-yl)ethyl]-2-fluoro-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -carboxamide; osteoporosis, periodontal disease, bone fracture, frailty, sarcopenia, depression, sexual dysfunction, and cognitive decline; tissue-selective androgen receptor modulators(SARM)
10/18/2007US20070243260 Treatment of Childhood Asthma
10/18/2007US20070243259 Nanoparticles for protein/peptide delivery and delivery means
10/18/2007US20070243256 Polyesteramide platform for site specific drug delivery
10/18/2007US20070243255 Multifunctional supramolecular hydrogels as biomaterials
10/18/2007US20070243253 Colonic drug delivery formulation
10/18/2007US20070243251 Dosage Forms Containing A PPI, NSAID, and Buffer
10/18/2007US20070243249 Novel formulation of pyridoxal-5'-phosphate and method of preparation
10/18/2007US20070243247 Dosage Form Containing The Active Ingredient Cholylsarcosine
10/18/2007US20070243244 Treating antibiotic-associated pseudomembranous colitis caused by C. difficile, and enterocolitis caused by S. aureus and associated MRSA strains
10/18/2007US20070243243 Oral dosage forms including an antiplatelet agent and an acid inhibitor
10/18/2007US20070243238 Treating mouth sores with patches adhered to teeth
10/18/2007US20070243233 Bioactive-rich concentrates and nutritive and therapeutic products containing same
10/18/2007US20070243231 Use of Whey Permeate for the Treatment of Metabolic Syndrome
10/18/2007US20070243224 Methods and compositions for treatment of lesioned sites of body vessels
10/18/2007US20070243222 Fungicidal formulation and method of use
10/18/2007US20070243221 Anti-wrinkle composition
10/18/2007US20070243218 Stabilized pentosan polysulfate (PPS) formulations and methods of analyzing them
10/18/2007US20070243217 Film-Shaped Medicament for Oral Administration Containing Estriol
10/18/2007US20070243216 Stable solutions of prostaglandin and uses of same
10/18/2007US20070243210 Methods and products for enhancing energy and nutrition in human beings
10/18/2007US20070243209 Compositions and methods for prevention and treatment of fungal diseases
10/18/2007US20070243192 Growth hormone receptor antagonist cancer treatment
10/18/2007US20070243191 Anti-hyperproliferative therapies targeting hdgf
10/18/2007US20070243186 ISLR gene and its association with osteoarthritis and other bone and cartilage disorders, expression products derived therefrom, and uses thereof
10/18/2007US20070243184 Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
1 ... 3540 3541 3542 3543 3544 3545 3546 3547 3548 3549 3550 3551 3552 3553 3554 3555 3556 3557 3558 3559 3560 ... 7860